BioPharma Today

Coming In Monday's "The Pink Sheet" DAILY - AstraZeneca Changes Plans For Recentin

AstraZeneca announced it will no longer file marketing applications in the U.S. and Europe this fall for Recentin (cediranib) in first-line metastatic colorectal cancer after the VEGF inhibitor failed to show an overall survival benefit in the Phase III HORIAON II study.

Respiratory Generics: Big Potential But A Tough Market To Crack

Article preview reprinted from "The Pink Sheet"- May 24, 2010

With GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity.

Latest News from "The Pink Sheet" DAILY - Pfizer Reports Outcomes Data For Inspra

Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart

Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population   read more

Editors' Picks from the World Press

Pipeline/RD News

• Study: GSK's adjuvanted H1N1 vaccine boosts response in children
• Clinical trial of Pfizer's Inspra shows early success
• Novartis' cancer drug fails to meet goal of Phase III trial

Business Finance

• Xanodyne appoints operations chief as CEO, president
• Teva decides to discontinue making propofol
• InNexus teams up with National Cancer Institute in antibody research

Government Legal News

• House panel discusses benefits of synthetic biology
• Experts weigh in on workplace safety at biotech companies
• FDA panel recommends approval of Theratechnologies' tesamorelin
• FDA might penalize JJ unit for manufacturing problems

Coming In Friday's "The Pink Sheet" DAILY - Pfizer's Inspra Reduces Risk of Cardiovascular Death

Pfizer is halting recruitment for its EMPHASIS-HF trial early after an interim analysis shows that patients treated with Inspra (eplerenone) plus standard of care experienced a significant reduction in risk of cardiovascular disease or heart failure hospitalization compared to those treated with standard of care plus a matching placebo.

Mylan Preps India Rollout - Latest From PharmAsia News

Massive U.S. Government Delegation Seeks Common Ground In China To Counter Threats To Peace And Health, Including Future Pandemics

05/27/10 12:44 GMT

Latest News From "The Pink Sheet" DAILY - FDA Partners With Drugs.com

R&D Swapping: AstraZeneca Lures Mackay From Pfizer To Head Global R&D

Editors' Picks From The World Press

Pipeline/RD News

• Salix gastric drug is linked to movement disorder

One From The Vaults: Our Interview With Mackay & Dolsten On Pfizer R&D

Today's story goes like this: AstraZeneca has snared Martin Mackay to head up its global R&D organization. Mackay, of course, previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team.

He led half of Pfizer's R&D engine; the other half was led by Mikael Dolsten, who until today was head of Pfizer BioTherapeutics and Vaccines R&D. Before that Dolsten was head of Wyeth R&D - now he's head of Pfizer's worldwide R&D.

Following so far?

Coming In Thursday's "The Pink Sheet" DAILY - R&D Managemetn Shifts Afoot At Big Pharma

AstraZeneca names Martin Mackay to the newly-created position of president of Global R&D. Mackay previously was head of Pfizer PharmaTherapeutics, responsible for Pfizer’s small molecules program and on the company’s executive leadership team.  Pfizer names Mikael Dolsten, previously head of Pfizer BioTherapeutics and Vaccines R&D organization, and before that head of Wyeth R&D, to be president of Pfizer’s worldwide R&D organization.